4.4 Article

Corneal Graft Rejection 10 Years After Penetrating Keratoplasty in the Cornea Donor Study

Journal

CORNEA
Volume 33, Issue 10, Pages 1003-1009

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ICO.0000000000000212

Keywords

corneal graft rejection; penetrating keratoplasty; corneal graft failure

Categories

Funding

  1. National Eye Institute, National Institutes of Health, Department of Health and Human Services [EY12728, EY12358]
  2. Eye Bank Association of America
  3. Bausch Lomb, Inc
  4. Tissue Banks International
  5. Vision Share, Inc
  6. San Diego Eye Bank
  7. Cornea Society
  8. Katena Products, Inc
  9. ViroMed Laboratories, Inc
  10. Michigan Eye-Bank
  11. Illinois Eye-Bank
  12. Cleveland Eye Bank
  13. Lions Eye Bank of New Jersey
  14. Konan Medical Corp
  15. Eye Bank for Sight Restoration
  16. SightLife
  17. Sight Society of Northeastern New York (Lions Eye Bank of Albany)
  18. Lions Eye Bank of Oregon
  19. Abbott Medical Optics
  20. Allergan
  21. Bausch Lomb
  22. Alcon Laboratories, Inc
  23. WaveTec Vision Systems, Inc
  24. Bio-Tissue

Ask authors/readers for more resources

Purpose: The aim of this study was to assess the effect of donor and recipient factors on corneal allograft rejection and evaluate whether a rejection event was associated with graft failure. Methods: One thousand ninety subjects undergoing penetrating keratoplasty for a moderate risk condition (principally Fuchs dystrophy or pseudophakic corneal edema) were followed for up to 12 years. Associations of baseline recipient and donor factors with the occurrence of a rejection event were assessed in univariate and multivariate proportional hazards models. Results: Among 651 eyes with a surviving graft at 5 years, the 10-year graft failure (+/- 99% confidence interval) rates were 12% +/- 4% among eyes with no rejection events in the first 5 years, 17% +/- 12% in eyes with at least 1 probable, but no definite rejection event, and 22% +/- 20% in eyes with at least 1 definite rejection event. The only baseline factor significantly associated with a higher risk of definite graft rejection was a preoperative history of glaucoma, particularly when previous glaucoma surgery had been performed and glaucoma medications were being used at the time of transplant (10-year incidence 35% +/- 23% compared with 14% +/- 4% in eyes with no history of glaucoma/intraocular pressure treatment, P = 0.008). Conclusions: Patients who experienced a definite rejection event frequently developed graft failure raising important questions as to how we might change acute and long-term corneal graft management. Multivariate analysis indicated that previous use of glaucoma medications and glaucoma filtering surgery was a significant risk factor related to a definite rejection event.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available